Is CloudMD (TSXV: DOC) a cheap telehealth stock to buy right now?

June 01, 2022 01:08 AM AEST | By Kajal Jain
 Is CloudMD (TSXV: DOC) a cheap telehealth stock to buy right now?
Image source: © 2022 Kalkine Media®

Highlights

  • CloudMD Software (TSXV:DOC) stock zoomed by nearly 27 per cent on Monday, May 30.
  • The Canadian healthcare tech firm saw revenue growth of 372 per cent in Q1 FY2022 compared to Q1 FY2021.
  • CloudMD has introduced a new brand identity, Kii Personalized & Connected Care recently.

Stocks of CloudMD Software (TSXV:DOC) zoomed by nearly 27 per cent on Monday, May 30, after it reported a significant revenue surge in its first-quarter results for fiscal 2022. The Canadian healthcare tech company said that it achieved revenue growth of 372 per cent in Q1 FY2022 compared to Q1 FY2021.

CloudMD also recently introduced a new brand identity, Kii Personalized & Connected Care, to offer a full spectrum of mental and physical health solutions.

Let us discuss CloudMD’s latest quarter results and stock performance to assess if DOC stock is a cheap option to explore at its current price.

CloudMD Software & Services (TSXV: DOC) Q1 FY2022 results

CloudMD Software reported C$ 41.4 million in revenue in the latest quarter, up from C$ 8.8 million in Q1 2021. The company also pointed out that its latest revenue was higher than C$ 38.7 million earned in the last quarter of FY2021.

The health company said that its gross profit margin increased to 32.5 per cent in Q1 2022 compared to 30 per cent in the previous quarter. However, its gross profit margin was lower than 40.9 per cent posted in Q1 2021.

CloudMD also narrowed its net loss to C$ 5.6 million in the first three months of FY2022 against C$ 15.1 million in Q4 2021. However, the company recorded an increase in a net loss in the latest quarter when compared to a loss of C$ 5.3 million incurred in the same period a year ago.

The healthcare firm said that the acquisition of MindBeacon and net cash acquired resulted in increased cash and cash equivalents (CCE) of C$ 46.9 million by the end of Q1 FY2022.

CloudMD Software & Services <a class='font-weight-bold' style='border-bottom: 2px dashed;' aria-label='https://kalkinemedia.com/ca/companies/tsxv-doc'  href='https://kalkinemedia.com/ca/companies/tsxv-doc'>(TSXV:DOC)</a> Q1 FY2022 results

Also read: Monkeypox spreads in Canada: 5 vaccine stocks to keep on your radar

CloudMD Software stock performance

Stocks of CloudMD Software tanked by roughly 56 per cent year-to-date (YTD). However, the health tech stock jumped by over 42 per cent from a 52-week low of C$ 0.365 (May 12).

As per Refinitiv data, DOC’s Relative Strength Index (RSI) value of 54.33 on May 30, was up from 30 (which represents an oversold market situation). The Moving Average Convergence/ Divergence (MACD) indicator was below the baseline but appears to be heading up. However, there is no guarantee that such trends may continue or not.

Bottomline

CloudMD Software Services is focused on providing personalized healthcare services to individuals to improve their health conditions and boost the company’s return on investment (ROI). CloudMD also said that it aims to streamline its operations by promoting organic growth and operational excellence in the near term with financial sustainability.

Also read: Celebrate Mental Health Awareness month with these Canadian stocks

Please note, the above content constitutes a very preliminary observation based on the industry, and is of limited scope without any in-depth fundamental valuation or technical analysis. Any interest in stocks or sectors should be thoroughly evaluated taking into consideration the associated risks. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.